Compare iShares Global Clean Energy ETF (ICLN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Incyte Corporation — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.27B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 10.1× iShares Global Clean Energy ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Incyte Corporation for 33 Days on average.
| ICLN | INCY | |
|---|---|---|
Market Cap | $2.27B | $22.85B |
Volume | 6,845,064 | 1,927,029 |
52-Week High | $23.75 | $129.93 |
52-Week Low | $15.78 | $83.80 |
Typical Hold Time | 87 Days | 33 Days |
Sector | — | Health |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.28, down 0.17% with a bearish technical outlook showing 14 sell signals versus 3 buy signals. The ETF faces headwinds from higher volatility and expense ratios compared to traditional energy ETFs, though clean energy benefits from global renewable energy acceleration driven by geopolitical tensions and data center power demand growth.
The fund's broader diversification across 105 global clean energy companies provides exposure to the energy transition theme, but investors face risks from competitive pressure from higher-yielding traditional energy ETFs and significant historical drawdowns of 57.2% that highlight the sector's volatility.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
